/
Our Company We are a late-stage clinical drug platform company addressing neurodegeneration, such as Alzheimer s disease ( AD ) and Parkinson s disease ( PD ). We are developing our lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$41M
▼ -17.3% YoY
Op. Margin
—
ROIC
-254.36%
▲ +273.8pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$27M
▼ -17.0% YoY
Net Debt
-$14M
Net Cash Position
Cash & Equiv.
$14M
Continue Research